Catestatin is useful in detecting patients with stage B heart failure

Area of Science:

• Cardiology
• Biomarkers
• Heart Failure Research

Background:

• Heart failure (HF) poses a significant health burden.
• Early detection of HF, particularly stage B, is vital for reducing morbidity.
• Catestatin's role as a potential biomarker in cardiovascular disease requires further investigation.

Purpose of the Study:

• To investigate catestatin levels across different stages of heart failure (HF).
• To assess the diagnostic value of catestatin for identifying stage B HF.
• To establish a potential cutoff value for catestatin in detecting stage B HF.

Main Methods:

• Inclusion of 300 patients with varying stages of HF.
• Measurement of serum catestatin levels.
• Performance of B-type natriuretic peptide (BNP) testing and echocardiography for HF staging.

Main Results:

• Catestatin levels demonstrated a gradual decrease from stage A to stage C of HF.
• A statistically significant difference in catestatin levels was observed between stage A and stage B HF.
• A catestatin cutoff value of 19.73 ng/ml was identified for detecting stage B HF, exhibiting 90% sensitivity and 50.9% specificity.

Conclusions:

• Catestatin levels vary across HF stages, suggesting its potential as a biomarker.
• Catestatin shows promise as a diagnostic tool for identifying patients with stage B HF.
• Further research may validate catestatin as a novel method for early HF detection and management.